Ryan W Chau

Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905).

Courtney A. Cullis, Mansoureh Rezaei, M. Sintchak, 2012, Journal of medicinal chemistry.

MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors

Suresh K Balani, Rachel E. Gershman, G. Weatherhead, 2015, ACS medicinal chemistry letters.

Discovery and optimization of pyrazoline compounds as B-Raf inhibitors.

S. Langston, K. Garcia, C. Blackburn, 2010, Bioorganic & medicinal chemistry letters.

Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor.

Pooja Shah, Hua Liao, John Newcomb, 2017, Nature chemical biology.

Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer.

Xingyue He, M. Mizutani, T. Soucy, 2021, Journal of medicinal chemistry.

Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.

Yuan Tian, Hongbo Zeng, Mansoureh Rezaei, 2011, Journal of medicinal chemistry.

Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors.

Michael J. Ardolino, Karin M. Otte, M. Kennedy, 2021, Journal of medicinal chemistry.

Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease.

Theodore A. Martinot, Michael J. Ardolino, Matthew L. Maddess, 2022, Journal of medicinal chemistry.

Identification and structure-activity relationships of a new series of Melanocortin-4 receptor antagonists.

C. Claiborne, C. Blackburn, T. Vos, 2006, Bioorganic & medicinal chemistry letters.